QIAGEN enters into broad collaboration agreement with Lilly for the development and commercialization of companion diagnostics

  • Email
  • Print
  • Arrangement to facilitate future collaborations in personalized medicine
  • Provides framework to develop and commercialize QIAGEN companion diagnostics paired with Lilly medicines in an effort to improve outcomes for individual patients
  • Builds on the two companies¹ recent mutual successes

Hilden, Germany, and Germantown, Maryland, February 13, 2013 ‹ QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) today announced it has entered into a master collaboration agreement with Eli Lilly and Company (NYSE: LLY) for the development and commercialization of companion diagnostics for pairing with Lilly investigational and approved medicines across all therapeutic areas. The agreement builds on QIAGEN and Lilly¹s past work together. Companion diagnostics unlock a patient¹s molecular information in order to guide treatment decisions for specific cancers or other diseases. Financial terms of the agreement are not being disclosed.

The agreement provides a framework for Lilly and QIAGEN to collaborate on future projects ­ across all of Lilly¹s therapeutic areas ­ aimed at bringing to market Lilly medicines paired with QIAGEN diagnostics. It also further underscores QIAGEN¹s leading position in partnering with global pharmaceutical companies to deliver the benefits of personalized medicine to patients and healthcare providers.
³Tailored therapies are a key component of Lilly¹s strategy of providing improved outcomes for individual patients. By working with partners like QIAGEN, we are advancing a number of tailored therapeutics in an effort to target the right medicine to the right patient,² said Daniel Skovronsky, M.D., Ph.D., vice president, tailored therapeutics, Lilly, and chief executive officer, Avid Radiopharmaceuticals, a wholly-owned subsidiary of Lilly. ³This collaboration with QIAGEN extends our capabilities to more quickly and cost-effectively bring innovative new medicines, alongside advanced diagnostics, to patients worldwide who are waiting.²

³We have expanded this relationship with Lilly as a result of our ongoing work together,² said Dr. Ulrich Schriek, Senior Vice President Global Business Development of QIAGEN. ³This agreement lays the groundwork for potential future projects with Lilly in various therapeutic areas and enables significant efficiencies for future development programs by standardizing interfaces and processes between our organizations. Through partnerships like this, QIAGEN offers pharma companies a cost-effective way to maximize the value and benefits of potential new medicines in their pipelines, while also reducing the risks in medicine development.²

QIAGEN is at the forefront globally in developing and validating Personalized Healthcare tests that provide physicians with genomic information on each patient to guide the selection of medicines in treating cancer and other diseases. QIAGEN is actively expanding its pipeline of tests for important biomarkers and intends to submit several companion diagnostics for U.S. regulatory approval. Last month, QIAGEN announced submission of its therascreen® EGFR RGQ PCR Kit test to the FDA as a proposed companion diagnostic to guide treatment with a new investigational oncology compound developed by Boehringer Ingelheim. QIAGEN is engaged in more than 15 projects with leading pharmaceutical and biotech companies to co-develop and market companion diagnostics.

QIAGEN and Lilly have previously collaborated on companion diagnostics designed to run on QIAGEN's Rotor-Gene Q system, a component of the QIAsymphony family of automated instruments, which is revolutionizing laboratory workflows. QIAGEN¹s strategy is to develop FDA-approved diagnostics in the United States for use on this platform.

About QIAGEN:

QIAGEN N.V., a Netherlands holding company, is the leading global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular information. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are then used to make these isolated biomolecules visible and ready for interpretation. QIAGEN markets more than 500 products around the world, selling both consumable kits and automation systems to customers through four customer classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of December 31, 2012, QIAGEN employed approximately 4,000 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com/.

Contact:

Corporate Communications:
Public Relations
Dr. Thomas Theuringer
Director Public Relations
+49 2103 29 11826
+1 240 686 7425
Email: PR@qiagen.com
www.twitter.com/qiagen
www.qiagen.com/about/press

Investor Relations

John Gilardi
VP Head of Corporate Communications
+1 240 686 2222

Peter Vozzo
Director, Global Investor Relations
+1 240 686 7400
Email: IR@qiagen.com
www.qiagen.com/about/investorrelation

  • <<
  • >>